Table 2.

The 5-year overall survival (OS) and disease-free survival (DFS) predictions of PrognosTILs according to outcome. Significant differences were detected between OS predictions of patients who died of disease and patients alive, and DFS predictions of patients with and without recurrence

PrognosTILs predictions			average		median		range		Wilcoxon-test
	n	%	OS	DFS	OS	DFS	OS	DFS	pOS = 0.015
Patients deceased due to tumor	14	15.0	80.1	80.6	80	76	74–92%	69–92%
Patients alive	79	85.0	85	82	85	83	49–95%	44–95%
Patients with recurrence	27	29.0	80.3	77.3	80	77	49–93%	44–93%	pDFS < 0.001
Patients alive with recurrence	13	14.0	80.6	77.7	83	80	49–93%	44–93%
Patients alive without recurrence	66	71.0	85.8	84	86	83	71–95%	67–95%
All (where PrognosTILs was evaluated)	93	100.0	84.2	81.7	84	82	49–95%	44–95%